Economic evaluation of add-on levetiracetam for the treatment of refractory partial epilepsy in Korea

Psychiatry Investigation

Volumn 6, Issue 3, 2009, Pages 185-193

  Suh, Guk Hee ^a   Lee, Sang Keol ^a  

^a Hallym University Medical Center   (South Korea)

Author keywords

Cost; Epilepsy; Levetiracetam; Partial seizures; Quality adjusted life year; Seizure free day

Indexed keywords

ETIRACETAM;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG DOSE ESCALATION; ECONOMIC EVALUATION; FEMALE; FOCAL EPILEPSY; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

EID: 70350046269     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2009.6.3.185     Document Type: Article

References (27)

1. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg and Psychiatry 1996;61:433-443.
2. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet 1995;346:140-144.
3. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30: 389-399.
4. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3,000 mg/d in patients with refractory partial seizures: a multicentre, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000;41:1276-1283. (Pubitemid 30766152)
5. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242. (Pubitemid 30604624)
6. Shorvon SD, Löwenthal A, Janz D, Bielen E, Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000;41:1179-1186. (Pubitemid 30692334)
7. Patsalos PN. LEV: Chemistry, biotransformation, pharmacokinetics, and drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002, p.428-432.
8. Perucca E, Johannessen SI. The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? Epileptic Disorders 2003;5 suppl:S17-S26.
9. Zhao Q, Jiang J, Li X, Lu ZS, Hu P. Single-dose pharmacokinetics of levetiracetam in healthy Chinese male subjects. Br J Clin Pharmacol 2007;63:614-617. (Pubitemid 46632565)
10. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adults. Clin Pharmacokinet 2007;46:503-512. (Pubitemid 46827859)
11. Luce BR, Elixhauser A. Standards for the Socioeconomic Evaluation of Health of Health Care Services. London: Springer-Verlag; 1990.
12. Heo K, Lee BI, Yi SD, Huh K, Kim JM, Lee SA, et al. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Seizure 2007;16:402-409. (Pubitemid 46844689)
13. Cramer JA, Perrine K, Devinsky O, Bryant-Comstock L, Meador K, Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998;39:81-88. (Pubitemid 28116846)
14. May TW, Pfäfflin M, Cramer JA. Psychometric properties of the German translation of the QOLIE-31. Epilepsy & Behav 2001;2:106-114. (Pubitemid 33585776)
15. Beghi E, Niero M, Roncolato M. Validity and reliability of the Italian version of the Quality-of-Life in Epilepsy Inventory (QOLIE-31). Seizure 2005;14:452-458. (Pubitemid 41548599)
16. Piperidou H, Terzoudi A, Vorvolakos T, Davis E, Heliopoulos I, Vadikolias K, et al. The Greek version of the Quality of Life in Epilepsy Inventory (QOLIE-31). Qual Life Res 2006;15:833-839.
17. Devinsky O, Vickrey BG, Cramer J, Perrine K, Hermann B, Meador K, et al. Development of the quality of life in epilepsy inventory. Epilepsia 1995;36:1089-1104.
18. Meencke HJ, Buyle S. Assessment of a dose-response relationship of levetiracetam. Eur J Neurol 2006;13:942-946.
19. Blais L, Sheehy O, St-Hilaire JM, Bernier G, Godfroid P, LeLorier J. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy. Pharmacoeconomics 2005;23:493-503. (Pubitemid 40994137)
20. National Health Insurance Corporation. 2006 National Health Insurance Statistical Yearbook. Seoul: National Health Insurance Corporation; 2007.
21. National Health Insurance Corporation. Major Health Insurance statistics. Health Insurance Forum 2006;5:146-150.
22. Markowitz MA, Mauskopf JA, Halpern MT. Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology 1995;51:1026-1033.
23. LeLorier J, Godfroid P, Hart Y, Roberts R. Levetiracetam: an innovative and cost-effective add-on drug for refractory partial epilepsy. Expert Review of Pharmacoeconomics and Outcomes Research 2004;4:143-151.
24. Schachter SC, Sommerville KW, Ryan JE. A cost-effectiveness analysis of tiagabine, phenytoin, and carbamazepine adjunctive therapy for patients with complex partial seizure. Neurology 1999;52(suppl. 6):A143.
25. Messori A, Trippoli S, Becagli P, Cincotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998;53:421-427. (Pubitemid 28154742)
26. Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making 2008;28:66-89.
27. Jo MW, Yun SC, Lee SI. Estimating quality weights for EQ-5D health states with the time trade-off method in South Korea. Value in Health 2008;11:1186-1189.